Bristol-Myers Squibb Company or Amneal Pharmaceuticals, Inc.: Who Invests More in Innovation?

Bristol-Myers Squibb vs. Amneal: R&D Investment Showdown

__timestampAmneal Pharmaceuticals, Inc.Bristol-Myers Squibb Company
Wednesday, January 1, 20141067350004534000000
Thursday, January 1, 20151368700005920000000
Friday, January 1, 20162047470004940000000
Sunday, January 1, 20171919380006411000000
Monday, January 1, 20182104510006345000000
Tuesday, January 1, 20192022870006148000000
Wednesday, January 1, 202019058500011143000000
Friday, January 1, 202120956300010195000000
Saturday, January 1, 20222000460009509000000
Sunday, January 1, 20231677780009299000000
Monday, January 1, 202411159000000
Loading chart...

Unleashing insights

Innovation Investment: A Tale of Two Companies

In the competitive world of pharmaceuticals, innovation is key. Bristol-Myers Squibb Company and Amneal Pharmaceuticals, Inc. have been investing in research and development (R&D) to stay ahead. From 2014 to 2023, Bristol-Myers Squibb consistently outpaced Amneal, investing nearly 40 times more in R&D on average. In 2020, Bristol-Myers Squibb peaked with an investment of approximately $11 billion, a 150% increase from 2014. Meanwhile, Amneal's R&D spending remained relatively stable, with a slight increase of about 57% over the same period. This disparity highlights Bristol-Myers Squibb's aggressive strategy to lead in innovation, while Amneal maintains a more conservative approach. As the pharmaceutical landscape evolves, these investment trends could significantly impact each company's future market position.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025